Raphi Levy Sells Shares of Alpha Tau Medical

Raphi Levy, the Chief Financial Officer of Alpha Tau Medical Ltd. (NasdaqCM:DRTS), recently sold 20,000 shares of the company. This transaction, executed on June 25, 2026, was part of a planned sale and took place at an average price of $11 per share, resulting in a total value of $220,000.

Other Institutional Activity in Alpha Tau Medical

Several institutional investors have been active in Alpha Tau Medical. Hightower Advisors, LLC increased its holdings by 188,440 shares, bringing its total to 874,994 shares valued at approximately $6.19 million, marking a 27.4% increase. Aquamarine Financial (Cayman) Ltd opened a new position with 721,501 shares worth around $5.10 million. Apella Capital, LLC maintained its position with 382,284 shares, valued at about $3.07 million. UBS Group AG significantly increased its stake by 265,988 shares to hold a total of 286,688 shares valued at $2.03 million, a 1285.0% increase. Northcoast Asset Management LLC reduced its holdings by 10,720 shares, ending with 147,138 shares worth $1.04 million, a 6.8% decrease.

Alpha Tau Medical Ltd. Stock Down 25.7%

Shares of Alpha Tau Medical traded near $10.93 on Friday. The company, which operates in the biotechnology sector, has a market capitalization of approximately $1.01 billion. It currently has no meaningful P/E ratio due to lack of profitability, with a forward P/E of -21.7. The stock's 52-week range is between $2.87 and $11.62, with a 50-day moving average of $9.26 and a 200-day moving average of $6.46. Alpha Tau Medical has a beta of 1.202, indicating its volatility compared to the market. The company's current ratio is 7.786, and its quick ratio is 7.314, with a debt-to-equity ratio of 20.679.

Insider Buying and Selling at Alpha Tau Medical Ltd.

Alongside the recent sale on June 25, 2026, Raphi Levy has been actively trading shares of Alpha Tau Medical. On June 23, 2026, Levy sold 17,500 shares at an average price of $9.55, and earlier on June 3, 2026, he sold 32,500 shares at $10.84 without a planned strategy. Additionally, on February 25, 2026, Levy sold 10,000 shares at $7.40, and on January 13, 2026, he sold 15,000 shares at $7.09, all as planned transactions. Another insider, Amnon Gat, sold 87,010 shares at $6.94 on February 2, 2026, also under a planned sale.

Analysts Set New Price Targets

On June 4, 2026, Barclays maintained its "buy" rating on Alpha Tau Medical, setting a price target of $17. Piper Sandler maintained a "hold" rating with an $8 target on May 19, 2026. Ladenburg Thalmann and HC Wainwright & Co. both maintained "buy" ratings with price targets of $14 and $15, respectively, on May 12, 2026. The consensus among five analysts is a "buy" recommendation, with a mean price target of $14.20.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a clinical-stage biotechnology company based in Jerusalem, Israel. It focuses on developing and commercializing diffusing alpha-emitters radiation therapy, known as Alpha DaRT, for treating solid tumors. The company is involved in clinical trials for various cancers, including skin, oral, pancreatic, prostate, lung, liver, and breast cancers. Led by CEO Mr. Uzi Sofer, Alpha Tau Medical employs 121 people and collaborates strategically to advance its prostate cancer treatment.

Bottom Line

Raphi Levy's recent planned sale of shares in Alpha Tau Medical is part of ongoing insider activity at the company. Investors and analysts keep a close watch on such transactions for insights into the company's future prospects. However, it's important to remember that these insider trades are disclosed after they occur and may not reflect the current sentiment. Alpha Tau Medical's stock performance and institutional interest continue to be areas of focus for market participants.